Stay updated on Oral Upadacitinib in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the efficacy or safety evaluation of the investigational drug upadacitinib in treating moderate to severe Atopic Dermatitis in Brazil.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:56.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as body weight, chronic atopic dermatitis history, and prior treatment responses. Previously, this section had no information provided.
    Difference
    22%
    Check dated 2024-05-22T21:28:02.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:39:52.000Z thumbnail image

Stay in the know with updates to Oral Upadacitinib in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral Upadacitinib in Atopic Dermatitis Clinical Trial page.